Strong Q2 revenue growth driven by Elfabrio sales, profitable operations with $3.8M net income, robust cash position of $40.7M with zero debt, patent extension to 2035, new South Korea approval, and on-track clinical development of PRX-115 with Phase 2 results expected in H2 2027. Full-year guidance maintained and market opportunity expanding.
EC approval of the new dosing regimen validates the clinical efficacy and safety of pegunigalsidase alfa, and the company is entitled to a $25 million regulatory milestone payment. This approval enhances the product's market competitiveness and demonstrates successful partnership execution with Chiesi.
Articles that tag PLX but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
